secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2023-07-27T23:59:59+00:00
Accession:  0000917520-23-000060
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integra Q2 adj EPS $0.71, revenue $381M (-4.2%); FDA warning on Boston facility; guides down
--------------------------------------------------------------------------------

- Q2 GAAP diluted EPS $0.05 vs $0.54; adjusted EPS $0.71 vs $0.82; revenue $381.3M declined 4.2% reported, 2.7% organic.
- Codman Specialty Surgical organic growth 6.3%; Tissue Technologies organic decline 19.7% due to Boston recall impact.
- FDA warning letter (July 17, 2023) for Boston facility quality systems; does not restrict shipping but requires annual third-party audit for three years.
- Planning $125M share repurchase in Q3 under new $225M board authorization; replaced prior program.
- Updated FY2023 guidance: revenue $1.548-1.560B, adj EPS $3.10-3.18; Boston restart late Q4'23, commercial distribution mid-Q2'24.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752023000060/0000917520-23-000060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752023000060/iart-20230726.htm
  HTML page:      https://secwatch.observer/filing/0000917520-23-000060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer